Everything tagged "dividend" across the TickerSpark archives.
Essential Utilities is a regulated utility with steady water and gas operations, but heavy capital spending and leverage keep the stock in Hold territory. The American Water merger, rate cases, and infrastructure recovery are the main catalysts.
McKesson posted double-digit fiscal 2026 growth, led by oncology, multispecialty, and prescription technology services. The stock earns a Buy, but valuation and a leveraged balance sheet keep the upside more measured.
Disney posted 7% revenue growth, 21% segment operating income growth, and a 28% EPS jump in fiscal Q3 2026, with Experiences and Entertainment leading the rebound. Leverage and sports margin pressure keep the risk profile moderate, but improving Disney+ economics support a Buy.
Extra Space Storage is executing well operationally, with rising occupancy, stronger same-store NOI, and higher 2026 FFO guidance. But the stock’s premium valuation and meaningful leverage leave limited upside, supporting a Hold view.
Kraft Heinz is a branded-food turnaround with improving share trends, but declining revenue, weak volume, and elevated debt keep it in Hold territory. The stock offers a cash-rich, defensive profile, yet execution must improve before the upside case is convincing.
Gilead’s HIV franchise is accelerating, with Yeztugo, Trodelvy, and a stronger pipeline offsetting pressure in Veklury and cell therapy. The stock looks attractive for moderate-risk investors with a medium-term horizon.
Rockwell Automation is delivering strong sales, margin, and EPS growth, but the stock already prices in much of the recovery. Our view is Hold with a fair value near current levels.
Energy Transfer posted stronger Q1 EBITDA, lifted 2026 guidance, and is leaning on fee-based growth projects across gas, NGLs, and crude. The stock looks attractive for income investors, but heavy debt keeps the risk profile elevated.
Assurant’s B+ report highlights a durable B2B2C protection platform, strong Global Lifestyle momentum, and improving execution. Valuation is not cheap, but the stock still screens as a Buy with a $293 fair value.
Fresenius Medical Care is a Hold as improving margins and cost savings offset sluggish revenue growth and looming reimbursement pressure. The dialysis leader’s 5008X rollout and clinic rationalization support earnings, but the stock already sits near fair value.
Marriott delivered 17% adjusted EPS growth and 4.2% global RevPAR gains, supported by a nearly 618,000-room development pipeline. The Buy case is strong, but leverage and a rich valuation keep the risk profile elevated.
DEA offers a niche government-tenant REIT profile with long leases and high occupancy, but leverage and a rich valuation keep the stock in Hold territory.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime